AI-Powered Kidney Disease Research
CKD affects 37 million Americans and progresses to dialysis or transplant without intervention. AI agents research SGLT2 inhibitors, anti-fibrotic agents, and novel renoprotective strategies.
Standard of Care
SGLT2 inhibitors (dapagliflozin, empagliflozin — landmark DAPA-CKD and EMPA-KIDNEY trials), ACE-i/ARBs, finerenone (non-steroidal MRA), BP control, diabetes management, dialysis (ESRD), kidney transplant.
Prevalence
~37 million Americans (~15% of adults). ~800,000 with ESRD on dialysis or transplant. #9 cause of death in the US.
Key Biomarkers
- eGFR (estimated glomerular filtration rate)
- Urine albumin-creatinine ratio (UACR)
- Cystatin C
- KIM-1 (kidney injury molecule)
- NGAL (neutrophil gelatinase-associated lipocalin)
Emerging Research
SGLT2 inhibitors reducing CKD progression by 39% (DAPA-CKD) regardless of diabetes status — paradigm shift. Finerenone adding further protection on top of SGLT2i. Endothelin receptor antagonists (atrasentan) for proteinuria. Xenotransplantation (pig kidney transplants). Artificial kidneys in development. Anti-complement therapy for IgA nephropathy.
Frequently Asked Questions
How do SGLT2 inhibitors protect kidneys?
SGLT2 inhibitors reduce intraglomerular pressure by restoring tubuloglomerular feedback, decrease inflammation and fibrosis, improve endothelial function, and reduce albuminuria. The DAPA-CKD trial showed 39% reduction in CKD progression — effective even without diabetes. They've transformed nephrology practice.
What is xenotransplantation for kidney disease?
Genetically modified pig kidneys have been successfully transplanted into humans in 2024–2025, with recipients surviving months with functional grafts. Gene editing removes pig antigens that cause rejection. This could solve the organ shortage crisis — 100,000+ Americans are on the kidney transplant waitlist.